UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

January 6, 2022

(Date of the earliest event reported)

Simulations Plus, Inc.

(Exact name of registrant as specified in its charter)

California	001-32046	95-4595609
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

42505 10^th Street West, Lancaster, California 93534-7059

(Address of principal executive offices) (Zip Code)

661-723-7723

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	SLP	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition

On January 6, 2022, Simulations Plus, Inc., a California corporation (the “Company”), issued a press release announcing financial results for its first quarter of fiscal year 2022 ended November 30, 2021. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”).

Item 7.01

Regulation FD Disclosure

On January 6, 2022, as part of the press release referenced above, the Company announced that its board of directors has declared a quarterly cash dividend of $0.06 per share of common stock, payable on February 7, 2022 to shareholders of record as of January 31, 2022.

In addition, on January 6, 2022, the Company held an investor conference call reporting its financial results for its first quarter of fiscal year 2022 ended November 30, 2021. The PowerPoint presentation, which was used for this investor conference call, is attached as Exhibit 99.2 to this Report.

In accordance with General Instructions B.2 of Form 8-K, the information in this Report, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Report.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This Report, including the disclosures set forth herein and Exhibits 99.1 and 99.2 attached hereto, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes" and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Report or reports hereafter furnished, including in other publicly available documents filed with the Securities and Exchange Commission (the "Commission"), to the Company’s stockholders and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

	99.1	Press release issued on January 6, 2022.
	99.2	PowerPoint presentation used at the Investor Conference Call on January 6, 2022.
	104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SIMULATIONS PLUS, INC.


Dated: January 6, 2022	By: /s/ Will Frederick
	Will Frederick
	Chief Financial Officer

Exhibit 99.1

Simulations Plus Reports First Quarter Fiscal 2022 Financial Results

Total revenue growth of 16%; Software revenue growth of 19%; Diluted Earnings Per Share (EPS) growth of 25%

Board of Directors announces quarterly dividend of $0.06 per share

LANCASTER, CA, January 6, 2022 – Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its first quarter of fiscal 2022, ended November 30, 2021.

Shawn O’Connor, chief executive officer of Simulations Plus, said, “Our software business continued to deliver higher revenue and margins in the first quarter, supplemented by improving momentum in our services business, which returned the company to overall double-digit revenue growth. The reinvigorated growth enabled a 22% improvement in net income, demonstrating both the benefit of a higher software versus services revenue mix and the inherent leverage in our operating model.”

First Quarter Fiscal 2022 Financial Highlights (compared with the corresponding period last fiscal year):

Total revenue increased 16% to $12.4 million;

Software revenue increased 19% to $7.4 million, representing 59% of total revenue;

Services revenue increased 13% to $5.0 million, representing 41% of total revenue;

Gross profit increased 17% to $9.7 million; gross margin was 78%;

Net income and diluted EPS of $3.0 million and $0.15 compared to $2.5 million and $0.12, respectively;

Adjusted EBITDA of $5.3 million, representing 42% of total revenue.

Mr. O’Connor concluded, “Looking forward, we remain focused on our organic growth strategy driven by key initiatives, including investing in our sales and marketing function, cross-selling products and services, and continuing to enhance our industry leading software offerings with new and improved functionality and incremental capabilities. With a software business that continues to generate consistently high growth rates, and a consulting services business that’s growing its pipeline and backlog, we remain confident in achieving our 10-15% total revenue guidance for fiscal 2022.”

Quarterly Dividend

The company’s Board of Directors declared a cash dividend of $0.06 per share of the company’s common stock, payable on February 7, 2022, to shareholders of record as of January 31, 2022. The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report.

Webcast and Conference Call Details

Shawn O’Connor, chief executive officer, and Will Frederick, chief financial officer, will host a conference call and webcast today at 5 p.m. Eastern Time to discuss details of the company’s performance for the quarter and certain forward-looking information. The call may be accessed by registering here or by calling 1-201-389-0879. The webcast will be available on our website under Conference Calls & Presentations. A replay of the webcast will be available on the website approximately one hour following the call.

Non-GAAP Definition

Adjusted EBITDA is defined as earnings (loss) before interest, taxes, depreciation and amortization, stock-based compensation, and any acquisition or financial transaction-related expenses. Adjusted EBITDA represents a measure that we believe is customarily used by investors and analysts to evaluate the financial performance of companies in addition to the GAAP measures that we present. Our management also believes that Adjusted EBITDA is useful in evaluating our core operating results. However, Adjusted EBITDA is not a measure of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income or operating income as an indicator of our operating performance or to net cash provided by operating activities as a measure of our liquidity. The company’s Adjusted EBITDA measure may not provide information that is directly comparable to that provided by other companies in its industry, as other companies in its industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items.

About Simulations Plus

Serving clients worldwide for 25 years, Simulations Plus is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | LinkedIn.

Forward-Looking Statements

Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

Investor Relations Contacts:

Renee Bouche

Simulations Plus Investor Relations

661-723-7723

[email protected]

Brian Siegel

Hayden IR

346-396-8696

[email protected]

--Tables follow—

SIMULATIONS PLUS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(Unaudited)

	Three months ended November 30,
(in thousands, except per common share amounts)	2021			2020

Revenue
Software	$	7,362		$	6,212
Services		5,055			4,489
Total revenue		12,417			10,701
Cost of revenue
Software		735			812
Services		2,021			1,621
Total cost of revenue		2,756			2,433
Gross profit		9,661			8,268
Operating expenses
Research and development		882			809
Selling, general and administrative		4,988			4,408
Total operating expenses		5,870			5,217

Income from operations		3,791			3,051

Other income (expense)
Interest income		64			61
Change in value of contingent consideration		(121	)		(121	)
Gain on sale of assets		1			–
Gain on currency exchange		121			5
Total other income (expense), net		65			(55	)

Income before income taxes		3,856			2,996
Provision for income taxes		(830	)		(517	)
Net Income	$	3,026		$	2,479

Earnings per share
Basic	$	0.15		$	0.12
Diluted	$	0.15		$	0.12

Weighted-average common shares outstanding
Basic		20,150			19,930
Diluted		20,746			20,799

Other comprehensive income (loss), net of tax
Foreign currency translation adjustments		(237	)		–
Comprehensive income	$	2,789		$	2,479

SIMULATIONS PLUS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	(Unaudited)			(Audited)
(In thousands, except share and per share amounts)	November 30, 2021			August 31, 2021
ASSETS
Current assets
Cash and cash equivalents	$	41,680		$	36,984
Accounts receivable, net of allowance for doubtful accounts of $12 and $78		11,823			9,851
Revenue in excess of billings		1,483			3,150
Prepaid income taxes		584			1,012
Prepaid expenses and other current assets		1,676			1,696
Short-term investments		82,660			86,620
Total current assets		139,906			139,313
Long-term assets
Capitalized computer software development costs,
net of accumulated amortization of $14,734 and $14,438		8,189			7,646
Property and equipment, net		2,339			1,838
Operating lease right of use asset		1,146			1,276
Intellectual property, net of accumulated amortization of $6,873 and $6,516		10,112			10,469
Other intangible assets, net of accumulated amortization of $2,319 and $2,186		6,331			6,464
Goodwill		12,921			12,921
Other assets		50			51
Total assets	$	180,994		$	179,978

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable	$	19		$	387
Accrued payroll and other expenses		3,967			5,604
Contracts payable - current portion		4,671			4,550
Billings in excess of revenue		52			117
Operating lease liability, current portion		338			382
Deferred revenue		568			534
Total current liabilities		9,615			11,574

Long-term liabilities
Deferred income taxes, net		2,113			1,726
Operating lease liability		810			896
Total liabilities		12,538			14,196

Commitments and contingencies

Shareholders' equity
Preferred stock, $0.001 par value 10,000,000 shares authorized no shares issued and outstanding		–			–
Common stock, $0.001 par value and additional paid-in capital — 50,000,000 shares authorized, 20,168,796 and 20,141,521 shares issued and outstanding		134,512			133,418
Retained earnings		34,224			32,407
Accumulated other comprehensive loss		(280	)		(43	)
Total shareholders' equity		168,456			165,782
Total liabilities and shareholders' equity	$	180,994		$	179,978

SIMULATIONS PLUS, INC.

Trended Financial Information*

(Unaudited)

	2021								2022		2021		2022
(in millions except earnings per share amounts)	Q1		Q2		Q3		Q4		Q1		Fiscal Year		Fiscal YTD
Software revenue
Gastroplus	$	3.3	$	4.5	$	5.4	$	3.1	$	4.0	$	16.3	$	4.0
MonolixSuite		1.2		1.6		0.9		0.8		1.6		4.4		1.6
ADMET Predictor		1.2		1.2		1.5		1.2		1.5		5.0		1.5
Other		0.5		0.6		0.5		0.3		0.3		1.9		0.3
Total software revenue	$	6.2	$	7.8	$	8.3	$	5.4	$	7.4	$	27.7	$	7.4
Services revenue
PKPD	$	2.2	$	2.6	$	1.9	$	2.3	$	2.3	$	9.1	$	2.3
QSP/QST		1.1		1.7		1.2		1.1		1.5		5.1		1.5
PBPK		0.6		0.9		0.7		0.7		0.9		3.0		0.9
Other		0.5		–		0.6		0.3		0.4		1.4		0.4
Total services revenue	$	4.5	$	5.3	$	4.4	$	4.4	$	5.1	$	18.8	$	5.1
Total consolidated revenue	$	10.7	$	13.1	$	12.8	$	9.8	$	12.4	$	46.5	$	12.4

Gross Margin
Software		86.9%		89.0%		90.0%		85.0%		90.0%		88.0%		90.0%
Services		63.9%		61.0%		63.0%		55.0%		60.0%		61.0%		60.0%
Total		77.3%		77.9%		80.7%		71.7%		77.8%		77.2%		77.8%

Income from operations	$	3.1	$	3.5	$	4.5	$	0.2	$	3.8	$	11.3	$	3.8
Operating Margin		28.5%		26.6%		35.6%		1.8%		30.5%		24.2%		30.5%
Net Income	$	2.5	$	3.2	$	3.8	$	0.3	$	3.0	$	9.8	$	3.0
Diluted Earnings Per Share	$	0.12	$	0.15	$	0.18	$	0.01	$	0.15	$	0.47	$	0.15
Adjusted EBITDA	$	4.3	$	5.0	$	5.9	$	1.7	$	5.3		16.9	$	5.3
Cash Flow from Operations	$	5.3	$	1.3	$	4.3	$	8.3	$	3.6		19.2	$	3.6

Revenue Breakdown by Region
Americas	$	7.1	$	8.7	$	9.7	$	7.1	$	8.5		32.5	$	8.5
EMEA		2.5		3.1		1.5		0.9		3.0		7.9		3.0
Asia Pacific		1.1		1.4		1.7		1.8		0.9		6.0		0.9
Total consolidated revenue	$	10.7	$	13.1	$	12.8	$	9.8	$	12.4	$	46.6	$	12.4

Software Performance Metrics
Average Revenue per Customer (in thousands)
Commercial	$	74.0	$	84.0	$	98.0	$	65.0	$	71.0

Services Performance Metrics
Backlog	$	12.0	$	11.2	$	12.4	$	13.0	$	15.4

*Numbers may not add due to rounding

SIMULATIONS PLUS, INC.

Reconciliation of Adjusted EBITDA to Net Income

(Unaudited)

	2021												2022			2021			2022
(in millions)	Q1			Q2			Q3			Q4			Q1			Fiscal Year			Fiscal YTD
Net Income	$	2.5		$	3.2		$	3.8		$	0.3		$	3.0		$	9.8		$	3.0
Excluding:
Interest income and expense, net		(0.1	)		(0.0	)		(0.0	)		(0.0	)		(0.1	)		(0.2	)		(0.1	)
Provision for income taxes		0.5			0.2			0.7			(0.1	)		0.8			1.3			0.8
Depreciation and amortization		0.9			0.9			0.9			1.0			0.8			3.6			0.8
Stock-based compensation		0.5			0.7			0.6			0.6			0.6			2.4			0.6

Adjusted EBITDA	$	4.3		$	5.0		$	5.9		$	1.7		$	5.3		$	16.9		$	5.3

Exhibit 99.2

1 | NASDAQ: SLP Earnings Call – Q1 FY22 January 6, 2022 1

2 | NASDAQ: SLP With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties . Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements . Factors that could cause or contribute to such differences include, but are not limited to : our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market . Further information on our risk factors is contained in our quarterly and annual reports and filed with the U . S . Securities and Exchange Commission . Safe Harbor Statement

3 | NASDAQ: SLP First Quarter Highlights » Strong momentum to begin year » Continued Strong Software Performance » Service Business Recovery +16% Revenue Growth +25% Diluted EPS Growth +31% Backlog Growth » Bus. Dev. efforts paying off » Demonstrated Scientific leadership » New software releases » Service achievements

4 | NASDAQ: SLP MonolixSuite® GastroPlus® +35% Revenue Growth 5 Multi - year Licenses Signed 16 New $100k+ customers 21 Upsells » First sales through Chinese distributor » Added new distributor in Japan » Strong renewal upsells First Quarter Software Highlights +19% Revenue Growth 19 Peer reviewed journal articles published in Q1 ADMET Predictor® » New release during the quarter » Closed 2 AIDD module accounts +24% Revenue Growth

5 | NASDAQ: SLP First Quarter Services Highlights PKPD » Q1 project disruptions “normal” levels » Good underlying bookings activity - full pipeline of opportunities QSP/QST » IPFsym release » Breakthrough NASH findings open significant potential development opportunities PBPK » New FDA TCAT Ρ grant to enhance Gastroplus model +31% Backlog Growth 49% Projects Growth +13% Revenue Growth +4% Revenue Growth +31% Revenue Growth +37% Revenue Growth

6 | NASDAQ: SLP FY22 Outlook Growth Targets: 10% to 15% Total Revenue Growth 55% to 60% Software Revenue % of Total Revenue 40% to 45% Service Revenue % of Total Revenue Commentary: » Software business continues to show strong momentum. » Services business remains volatile, but long - term outlook remains unchanged; backlog increased in the quarter and pipeline activity is strong » M&A remains strategic enhancement to organic growth objectives

7 | NASDAQ: SLP Financial Results

8 | NASDAQ: SLP Q4 Revenue (in millions) +16% Total Revenue $4.6 $6.2 $7.4 $4.8 $4.5 $5.0 $9.4 $10.7 $12.4 1Q20 1Q21 1Q22 Software Services 58% 42% 1Q21 Mix Software Services 59% 41% 1Q22 Mix Software Services +19% Software Revenue +13% Services Revenue Revenue – Q1 (in millions)

9 | NASDAQ: SLP 82% 87% 90% 62% 64% 60% 72% 77% 78% 1Q20 1Q21 1Q22 Software Services Total Gross Margin Trends – Q1

10 | NASDAQ: SLP Software Revenue by Product Software Product as % of Software Revenue 54% 19% 19% 8% 1Q21 Other 54% 21% 20% 5% 1Q22 Other

11 | NASDAQ: SLP Software Performance Metrics – Q4 Avg. Revenue per Customer (in thousands) $59 $74 $71 1Q20 1Q21 1Q22 94% 87% 93% 98% 95% 96% 1Q20 1Q21 1Q22 Accounts Fees Software Performance Metrics – Q1 Commercial Customers University+ Licenses: 92 customers in 26 countries Renewal Rates

12 | NASDAQ: SLP Services Revenue by Type Services Types as % of Service Revenue 50% 25% 14% 11% PKPD QSP/QST PBPK Other YTD 1Q21 46% 29% 17% 8% PKPD QSP/QST PBPK Other 1Q22

13 | NASDAQ: SLP Services Performance Metrics $14 $12 $15 1Q20 1Q21 1Q22 Backlog (in millions) 56 58 67 27 12 22 42 41 64 15 33 125 126 186 1Q20 1Q21 1Q22 PKPD QSP/QST PBPK Other Backlog Services Performance Metrics Total Projects

14 | NASDAQ: SLP Income Statement Summary – Q1 (in millions, except EPS) 1Q22 % of Rev 1Q21 % of Rev Revenue $12.4 100% $10.7 100% Revenue Growth 16% 14% Gross profit 9.7 78% 8.3 77% R&D 0.9 7% 0.8 8% SG&A 5.0 40% 4.4 41% Total operating exp 5.9 47% 5.2 49% Income from operations 3.8 31% 3.1 29% Income before income taxes 3.9 31% 3.0 28% Income taxes (0.8) 7% (0.5) 5% Effective tax rate 22% 17% Net income $3.0 24% $2.5 23% Diluted earnings per share $0.15 $0.12 Adjusted EBITDA $5.3 42% $4.3 40%

15 | NASDAQ: SLP Balance Sheet Summary (in millions) Nov. 30, 2021 Aug. 31, 2021 Cash and short - term investments $124.3 $123.6 Total current assets 139.9 139.3 Total assets 181.0 180.0 Current liabilities 9.6 11.6 Long - term liabilities 2.9 2.6 Total liabilities 12.5 14.2 Shareholders’ equity 168.5 165.8 Total liabilities and shareholders’ equity 181.0 180.0

16 | NASDAQ: SLP Conclusion » Industry adoption of model informed drug development tools and techniques continues to expand » Scientific credibility with academia and regulatory agencies » Software business with accelerated revenue growth rates and expanded product functionality » Services business steadily normalizing with improved backlog and strong bookings SECURE LEADERSHIP POSITION IN BIOSIMULATION MARKET